# Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists

> **NCT03412058** · NA · ACTIVE_NOT_RECRUITING · sponsor: **UNICANCER** · enrollment: 670 (estimated)

## Conditions studied

- Melanoma
- Non Small Cell Lung Cancer
- Head and Neck Squamous Cell Carcinoma

## Interventions

- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Biopsy

## Key facts

- **NCT ID:** NCT03412058
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-27
- **Primary completion:** 2024-01-02
- **Final completion:** 2025-12
- **Target enrollment:** 670 (ESTIMATED)
- **Last updated:** 2025-02-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03412058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03412058, "Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03412058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*